Antineoplastics
1
Reactions 389 - 22 Feb 1992 Antineoplastics Disseminated intravascular coagulation: case report Hypercoagulability can complicate malignant disease and there have been reports that antineoplastic therapy can induce hypercoagulation in patients with breast cancer. This report presents a patient with lung cancer who developed disseminated intravascular coagulation after antineoplastic therapy. Lung cancer in a 73-year-old man was treated with cisplatin 100 mg/m2, vindesine 3 mg/m2, and oral tegafur 600 mg/day A sudden decrease in peripheral platelet count occurred 2 days after the first course of antineoplastic therapy, followed by a reduction in the plasma fibrinogen level and an increase in fibrin degradation products; these normalised within a week. After the second course of antineoplastic therapy 2 months later, the patient developed severe thrombocytopenia and purpura on his arms and chest wall. The peripheral platelet count returned to normal after continuous IV infusion of heparin 8000 U/day. Plasma, collected 1-3 days after antineoplastic therapy, contained thrombosis-inducing activity (TIA). The origin of TIA is not yet known but this case illustrates that it is induced in the circulation by antineoplastic agents. ’TIA may be responsible at least in part for alteration of blood coagulation activity seen after chemotherapy.’ Hayashi S, et al. Hypercoagulopathy induced by chemotherapy in a patient with lung cancer. A possible role for a factor with thrombosis-inducing activity. Chest 101: 277-278, Jan 1992 - Japan 800118510 1 Reactions 22 Feb 1992 No. 389 0114-9954/10/0389-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 389 - 22 Feb 1992
Antineoplastics
Disseminated intravascular coagulation: case reportHypercoagulability can complicate malignant disease and
there have been reports that antineoplastic therapy can inducehypercoagulation in patients with breast cancer. This reportpresents a patient with lung cancer who developeddisseminated intravascular coagulation after antineoplastictherapy.
Lung cancer in a 73-year-old man was treated with cisplatin100 mg/m2, vindesine 3 mg/m2, and oral tegafur 600 mg/dayA sudden decrease in peripheral platelet count occurred 2 daysafter the first course of antineoplastic therapy, followed by areduction in the plasma fibrinogen level and an increase infibrin degradation products; these normalised within a week.
After the second course of antineoplastic therapy 2 monthslater, the patient developed severe thrombocytopenia andpurpura on his arms and chest wall. The peripheral plateletcount returned to normal after continuous IV infusion ofheparin 8000 U/day. Plasma, collected 1-3 days afterantineoplastic therapy, contained thrombosis-inducing activity(TIA).
The origin of TIA is not yet known but this case illustratesthat it is induced in the circulation by antineoplastic agents.’TIA may be responsible at least in part for alteration of bloodcoagulation activity seen after chemotherapy.’Hayashi S, et al. Hypercoagulopathy induced by chemotherapy in a patient withlung cancer. A possible role for a factor with thrombosis-inducing activity. Chest101: 277-278, Jan 1992 - Japan 800118510
1
Reactions 22 Feb 1992 No. 3890114-9954/10/0389-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
